<unk>  has been used both as sole therapy and in combination with other agents including etoposide, fludarabine, mitoxantrone, methotrexate, prednisone, rituximab, vincristine and 90Y-ibritumomab tiuxetan. Lymphomas Adult Atypical Sporadic Burkitt Lymphoma successfully treated with<unk>  and Rituximab One combination for stage III/IV relapsed or refractory indolent lymphomas and mantle cell lymphoma (MCL), with or without prior rituximab-containing chemoimmunotherapy treatment, is<unk>  with mitoxantrone and rituximab. In Germany in 2012 it has become the first line treatment of choice for indolent lymphoma. After trial results released in June 2012 showed that it more than doubled disease progression-free survival when given along with rituximab. The combination also left patients with fewer side effects than the older R-CHOP treatment.
Bendamustine
Lomustine
Carmustine
Mannomustine
Ifosfamide
Normustine
Vincristine
Busulfan